Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment

• Published in: Molecular neurobiology 2022-04, Vol.59 (4), p.2190-2203
• Main Authors: Matusiak, Monika, Oziębło, Dominika, Ołdak, Monika, Rejmak, Emilia, Kaczmarek, Leszek, Skarżyński, Piotr Henryk, Skarżyński, Henryk
• Format: Article
• Language: English
• Subjects: Auditory plasticity; Biomarkers; Biomedical and Life Sciences; Biomedicine; Brain-Derived Neurotrophic Factor; Cell Biology; Child; Children; Cochlea; Cochlear Implantation; Cochlear Implants; Cohort analysis; Cohort Studies; Deafness; Deafness - genetics; Deafness - surgery; Gelatinase B; Genetic diversity; Humans; Infant; Matrix metalloproteinase; Matrix Metalloproteinase 9; Metalloproteinase; Neurobiology; Neurology; Neuronal Plasticity; Neuroplasticity; Neurosciences; Plasma levels; Prospective Studies; Sensory deprivation; Statistical analysis; Transplants & implants; Treatment Outcome
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-022-02732-7

Because of vast variability of cochlear implantation outcomes in prelingual deafness treatment, identification of good and poor performers remains a challenging task. To address this issue, we investigated genetic variants of matrix metalloproteinase 9 ( MMP9 ) and brain-derived neurotrophic factor ( BDNF ) and plasma levels of MMP-9, BDNF, and pro-BDNF that have all been implicated in neuroplasticity after sensory deprivation in the auditory pathway. We recruited a cohort of prelingually deaf children, all implanted before the age of 2, and carried out a prospective observation ( N  = 61). Next, we analyzed the association between (i) functional MMP9 (rs20544, rs3918242, rs2234681) and BDNF (rs6265) gene variants (and their respective protein levels) and (ii) the child’s auditory development as measured with the LittlEARS Questionnaire (LEAQ) before cochlear implant (CI) activation and at 8 and 18 months post-CI activation. Statistical analyses revealed that the plasma level of MMP-9 measured at implantation in prelingually deaf children was significantly correlated with the LEAQ score 18 months after CI activation. In the subgroup of DFNB1-related deafness ( N  = 40), rs3918242 of MMP9 was significantly associated with LEAQ score at 18 months after CI activation; also, according to a multiple regression model, the ratio of plasma levels of pro-BDNF/BDNF measured at implantation was a significant predictor of overall LEAQ score at follow-up. In the subgroup with DFNB1-related deafness, who had CI activation after 1 year old ( N  = 22), a multiple regression model showed that rs3918242 of MMP9 was a significant predictor of overall LEAQ score at follow-up.